Maravai Lifesciences Holdings, INC 8-K filings

Maravai LifeSciences announced second quarter 2026 financial results, reporting an 8.5% increase in total revenue to $51.4 million and raising its full-year Adjusted EBITDA guidance.

Maravai LifeSciences Holdings, Inc. announced the refinancing of its credit agreement, establishing a new $180 million facility and extending its term loan maturity to June 2032.

Maravai LifeSciences shareholders re-elected three directors and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

Maravai LifeSciences announced first quarter 2026 financial results, showing a 40.5% revenue increase to $65.8 million, a significant improvement in net loss, and positive free cash flow, leading to raised full-year guidance.

Maravai LifeSciences exceeded Q4 revenue expectations and returned to positive Adjusted EBITDA, guiding for 2026 revenue of $200M-$210M.

Maravai LifeSciences reported a net loss of $45.1 million and a 39.7% revenue decrease to $41.6 million in Q3 2025, driven by lower Nucleic Acid Production sales, while Biologics Safety Testing showed growth.

Maravai LifeSciences announced three voluntary board resignations and a reduction in board size to streamline governance and cut administrative expenses.

Maravai LifeSciences announced a significant Q2 2025 net loss and negative Adjusted EBITDA, alongside a major organizational restructuring impacting 25% of its workforce, aiming for over $50 million in annualized cost savings.

Maravai LifeSciences Holdings, Inc. has appointed Deloitte & Touche LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP, following EY's adverse opinion on the company's internal controls for 2024.

Maravai LifeSciences Holdings, Inc. announced the appointment of Rajesh Asarpota as its new Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde who will transition to an advisory role.

Maravai LifeSciences Holdings, Inc. has appointed Bernd Brust, a seasoned life sciences executive with a strong track record, as its new Chief Executive Officer and a Board member, succeeding William E. Martin, III, effective June 8, 2025.

Maravai LifeSciences Holdings, Inc. announced the successful election of four directors, ratification of Ernst & Young LLP as its independent auditor, and advisory approval of executive compensation at its 2025 Annual Meeting of Shareholders.

Maravai LifeSciences announced its Q1 2025 financial results, with revenue exceeding guidance but reporting a net loss and declining year-over-year revenue.

Maravai LifeSciences provides its financial outlook for 2025, anticipating revenue in the range of $185.0 million to $205.0 million.

Maravai LifeSciences reported a decrease in revenue for both Q4 and full year 2024, alongside a net loss, but highlighted strategic acquisitions and debt prepayment.

Maravai LifeSciences delays its Q4 and full year 2024 earnings release and 10-K filing due to issues with goodwill assessment, revenue recognition, and internal controls.

Maravai LifeSciences expects its 2024 revenue to be near the mid-point of its previously announced guidance range and will release full results on February 25, 2025.

Maravai LifeSciences has voluntarily prepaid $228 million of its term loan using cash on hand, significantly reducing its outstanding debt.

Maravai LifeSciences has appointed R. Andrew Eckert as Chairman of the Board, succeeding Carl Hull who is retiring, effective December 5, 2024.

Maravai LifeSciences reported a decrease in revenue and a significant net loss for the third quarter of 2024, while also announcing a strategic acquisition to expand its capabilities in nucleic acid-based therapies.

Maravai LifeSciences Holdings, Inc. has amended its credit agreement to extend the maturity date of its revolving credit facility by five years, subject to certain conditions.

Maravai LifeSciences announced a 6.5% year-over-year revenue increase for the second quarter of 2024, alongside a net loss of $14.5 million, while reaffirming its full-year revenue guidance.

Maravai LifeSciences has appointed its CEO, William Trey Martin, III, to its Board of Directors, effective July 31, 2024.

Anat Ashkenazi, a director at Maravai LifeSciences, has announced her resignation effective July 31, 2024, due to time commitments related to her new role as CFO of Alphabet Inc.

Maravai LifeSciences held its 2024 Annual Meeting of Shareholders, electing four directors and ratifying Ernst & Young LLP as its independent auditor.

Maravai LifeSciences reported a 19% year-over-year revenue decrease in Q1 2024, driven by lower demand for COVID-19 related products, but reaffirmed its full-year revenue guidance.

Maravai LifeSciences reported a significant decrease in revenue for both the fourth quarter and full year 2023, primarily due to reduced COVID-19 related demand, but provided 2024 revenue guidance.